Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma

被引:59
作者
Abdulkadir, SA
Carbone, JM
Naughton, CK
Humphrey, PA
Catalona, WJ
Milbrandt, J
机构
[1] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
关键词
early growth response gene 1; NAB2; prostate cancer; transcription;
D O I
10.1053/hupa.2001.27102
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The transcription factor EGR1 is frequently overexpressed in human prostate cancer and regulates the expression of several genes important for tumor progression. In addition, mice lacking the Egr1 gene show a defect in prostate tumorigenesis. NAB2 is a novel corepressor molecule that modulates EGR1 activity and is induced by the same stimuli that induce EGR1. The human NAB2 gene has been localized to 12q13.3-14.1, within a chromosomal region that is thought to harbor a prostate tumor suppressor. We have examined the expression of NAB2 in human prostate carcinoma specimens. We show here that NAB2 protein expression is lost in a majority of primary prostate carcinoma specimens, including many samples that have high EGR1 levels. This loss occurs early in the tumorigenic process and is sustained, as it is seen in precursor prostatic intraepithelial neoplasia lesions as well as in metastases. Furthermore, loss of NAB2 did not correlate with the tumor grade or stage. Our findings suggest that high levels of EGR1 coupled with low levels of NAB2 can result in high, unrestrained EGR1 transcriptional activity in human prostate cancers. Copyright (C) 2001 by W.B. Saunders Company
引用
收藏
页码:935 / 939
页数:5
相关论文
共 19 条
[1]   Impaired prostate tumorigenesis in Egr1-deficient mice [J].
Abdulkadir, SA ;
Qu, ZC ;
Garabedian, E ;
Song, SK ;
Peters, TJ ;
Svaren, J ;
Carbone, JM ;
Naughton, CK ;
Catalona, WJ ;
Ackerman, JJH ;
Gordon, JI ;
Humphrey, PA ;
Milbrandt, J .
NATURE MEDICINE, 2001, 7 (01) :101-107
[2]  
Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO
[3]  
2-S
[4]  
Barrack ER, 1997, PROSTATE, V31, P61
[5]  
BERUBE NG, 1994, CANCER RES, V54, P3077
[6]  
DAY ML, 1990, J BIOL CHEM, V265, P15253
[7]  
DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO
[8]  
2-E
[9]  
Eid MA, 1998, CANCER RES, V58, P2461
[10]  
FUDGE K, 1994, MODERN PATHOL, V7, P549